drugset / Trial / NCT01808326

A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia

NCT01808326

Phase 2 Completed 5 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, single arm, phase II study of chlorambucil in subjects with previously untreated CLL. The primary objective is to evaluate the response to chlorambucil in Japanese subjects with previously untreated CLL. Secondary objectives are to evaluate efficacy, safety and pharmacokinetics of chlorambucil in Japanese subjects.

Timeline

Start
2013-04
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Chlorambucil Other / unclassified 10 mg/m2 Oral